Danaher Corporation (DHR)
| Market Cap | 155.75B +12.5% |
| Revenue (ttm) | 25.11B +4.6% |
| Net Income | 4.00B +17.3% |
| EPS | 5.63 +19.6% |
| Shares Out | 702.99M |
| PE Ratio | 39.46 |
| Forward PE | 25.04 |
| Dividend | $1.60 (0.72%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 3,404,584 |
| Open | 221.27 |
| Previous Close | 221.09 |
| Day's Range | 219.92 - 223.42 |
| 52-Week Range | 160.93 - 242.80 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 230.83 (+4.18%) |
| Earnings Date | Oct 21, 2026 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for DHR stock is "Buy." The 12-month stock price target is $230.83, which is an increase of 4.18% from the latest price.
News
Danaher Schedules Third Quarter 2026 Earnings Conference Call
WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 20...
Danaher Announces Quarterly Dividend
WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common s...
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer
Rainer Blair to retire WASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer ...
Don't Quit on Danaher Stock After Horrific Earnings Reaction
There's reason to believe the stock can stage a comeback after its worst day in two decades.
Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise
Danaher raised its annual profit forecast on Tuesday, but shares fell nearly 12% in premarket trading after the life sciences firm trimmed its core revenue growth outlook and reported weaker-than-exp...
Danaher Earnings Call Transcript: Q2 2026
Q2 saw better-than-expected revenue, earnings, and cash flow, with strong life sciences and diagnostics performance. Raised full-year core revenue and EPS guidance, closed Masimo acquisition early, and saw robust order growth despite bioprocessing shipment delays.
Danaher Quarterly report: Q2 2026
Danaher has published its Q2 2026 quarterly earnings report on July 21, 2026.
Danaher Earnings release: Q2 2026
Danaher released its Q2 2026 earnings on July 21, 2026, summarizing the period's financial results.
Danaher Slides: Q2 2026
Danaher has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Danaher Reports Second Quarter 2026 Results
WASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period...
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
WASHINGTON, June 29, 2026 /PRNewswire/ -- The Danaher Foundation, supported by Danaher Corporation (NYSE: DHR), today announced a $1 million commitment to support urgent, on-the-ground response to the...
The Big 3: JPM, DHR, MRK
Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in M...
Danaher Schedules Second Quarter 2026 Earnings Conference Call
WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 be...
Danaher Completes Acquisition of Masimo Corporation
WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a lea...
Sirius XM Holdings Set to Join S&P MidCap 400
NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11....
SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #massspec--SCIEX advances the ZenoTOF line with platform-wide expansions in software, integrations, and key collaborations.
SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #V55--SCIEX launches the novus V55 system with SCIEX OS 5.0 software and AI enablement tools.
Danaher Transcript: Bank of America Global Healthcare Conference 2026
Solid first quarter with 300 basis points of core growth, strong bioprocessing and diagnostics momentum, and robust performance in life sciences. Guidance for 3%-6% organic growth is maintained, with headwinds expected to fade and capital deployment focused on M&A and strategic investments.
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Heal...
Danaher Transcript: AGM 2026
The meeting covered director elections, auditor reappointment, executive compensation, and incentive plan approval, all passing with strong majorities. Financial results showed $24.6B in revenue, high margins, and strong recurring revenue, with a focus on life sciences and diagnostics.
Masimo Shareholders Approve Acquisition by Danaher
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to...